Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
Vaxcyte (Nasdaq: PCVX) announced a webcast and conference call on September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study of VAX-31, their 31-valent pneumococcal conjugate vaccine (PCV) candidate. The study evaluated the safety, tolerability, and immunogenicity of VAX-31 in healthy adults aged 50 and older. VAX-31 is designed to prevent invasive pneumococcal disease (IPD). Interested parties can participate via phone (800-225-9448 domestic, 203-518-9708 international) using conference ID PCVX0903 or through a live webcast on Vaxcyte's investor relations page. The webcast will be archived for 30 days after the event.
Vaxcyte (Nasdaq: PCVX) ha annunciato un webcast e una conference call il 3 settembre 2024 alle 8:00 ora orientale per presentare i risultati preliminari dello studio di Fase 1/2 di VAX-31, il loro candidato vaccino coniugato pneumococcico a 31 valenti (PCV). Lo studio ha valutato la safety, tollerabilità e immunogenicità di VAX-31 in adulti sani di età pari o superiore a 50 anni. VAX-31 è progettato per prevenire la malattia pneumococcica invasiva (IPD). I soggetti interessati possono partecipare tramite telefono (800-225-9448 per le chiamate nazionali, 203-518-9708 per le chiamate internazionali) utilizzando l'ID conferenza PCVX0903 o attraverso un webcast dal sito delle relazioni con gli investitori di Vaxcyte. Il webcast sarà archiviato per 30 giorni dopo l'evento.
Vaxcyte (Nasdaq: PCVX) anunció un webcast y una conferencia telefónica el 3 de septiembre de 2024 a las 8:00 a.m. hora del Este para presentar los resultados preliminares del estudio de Fase 1/2 de VAX-31, su candidato a vacuna conjugada neumocócica de 31 valencias (PCV). El estudio evaluó la seguridad, tolerabilidad e inmunogenicidad de VAX-31 en adultos sanos de 50 años o más. VAX-31 está diseñado para prevenir la enfermedad neumocócica invasiva (IPD). Las partes interesadas pueden participar por teléfono (800-225-9448 nacional, 203-518-9708 internacional) utilizando el ID de conferencia PCVX0903 o a través de un webcast en la página de relaciones con inversionistas de Vaxcyte. El webcast se archivará durante 30 días después del evento.
Vaxcyte (Nasdaq: PCVX)는 2024년 9월 3일 오전 8시 동부 표준시(Eastern Time)에 VAX-31의 1/2상 연구 결과, 31가 폐렴구균 결합백신(PCV) 후보를 발표하기 위한 웹캐스트 및 콘퍼런스 콜을 발표했습니다. 이 연구는 50세 이상의 건강한 성인을 대상으로 VAX-31의 안전성, 내약성, 면역원성을 평가했습니다. VAX-31은 침습성 폐렴구균 질병(IPD)을 예방하기 위해 설계되었습니다. 관심 있는 분들은 전화(국내 800-225-9448, 국제 203-518-9708)를 통해 PCVX0903 회의 ID를 사용하거나 Vaxcyte의 투자자 관계 페이지에서 실시간 웹캐스트에 참여할 수 있습니다. 이 웹캐스트는 행사 후 30일 동안 아카이브됩니다.
Vaxcyte (Nasdaq: PCVX) a annoncé un webcast et une conférence téléphonique le 3 septembre 2024 à 8h00, heure de l'Est, pour présenter les résultats préliminaires de l'étude de Phase 1/2 de VAX-31, leur candidat vaccin conjugué pneumococcique à 31 valences (PCV). L'étude a évalué la safety, tolérance et immunogénicité de VAX-31 chez des adultes en bonne santé âgés de 50 ans et plus. VAX-31 est conçu pour prévenir la maladie pneumococcique invasive (IPD). Les parties intéressées peuvent participer par téléphone (800-225-9448 pour les appels nationaux, 203-518-9708 pour les appels internationaux) en utilisant l'ID de conférence PCVX0903 ou via un webcast en direct sur la page des relations investisseurs de Vaxcyte. Le webcast sera archivé pendant 30 jours après l'événement.
Vaxcyte (Nasdaq: PCVX) kündigte am 3. September 2024 um 8:00 Uhr Eastern Time ein Webcast und eine Telefonkonferenz an, um die Ergebnisse der Phase 1/2-Studie von VAX-31, ihrem 31-valenten pneumokokken Konjugatimpfstoff (PCV), vorzustellen. Die Studie bewertete die Sicherheit, Verträglichkeit und Immunogenität von VAX-31 bei gesunden Erwachsenen im Alter von 50 Jahren und älter. VAX-31 soll invasive pneumokokkenkrankheit (IPD) verhindern. Interessierte Parteien können telefonisch teilnehmen (800-225-9448 für nationale Anrufe, 203-518-9708 für internationale Anrufe), indem sie die Konferenz-ID PCVX0903 verwenden oder über einen Live-Webcast auf der Investor Relations-Seite von Vaxcyte. Der Webcast wird 30 Tage nach der Veranstaltung archiviert.
- Vaxcyte is presenting topline results from a Phase 1/2 study of VAX-31
- VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate, potentially offering broader protection
- The study focuses on adults aged 50 and older, a key demographic for pneumococcal vaccines
- None.
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older.
To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVX0903. A live webcast of the conference call will also be available on the investor relations page of the Vaxcyte corporate website at www.vaxcyte.com. After the live webcast, the event will remain archived on the Vaxcyte website for 30 days.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a Phase 3-ready 24-valent, broad-spectrum, carrier-sparing PCV being developed for the prevention of IPD. VAX-31, the Company’s next-generation 31-valent PCV, is the broadest-spectrum PCV candidate in the clinic today. Both VAX-24 and VAX-31 are designed to improve upon the standard-of-care PCVs for both children and adults by covering the serotypes that are responsible for a significant portion of IPD in circulation and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.
Contacts:
Patrick Ryan, Executive Director, Corporate Communications
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor Relations
Vaxcyte, Inc.
860-729-8902
investors@vaxcyte.com
FAQ
What is the purpose of Vaxcyte's September 3, 2024 webcast and conference call?
What did the Phase 1/2 study of VAX-31 (PCVX) evaluate?
How can investors participate in Vaxcyte's (PCVX) September 3, 2024 conference call?
What disease is Vaxcyte's VAX-31 (PCVX) designed to prevent?
